(Total Views: 388)
Posted On: 09/09/2021 12:59:48 PM
Post# of 153986
100% agree. This is not Papa's biotech.
In this case, it is more about the path to success than the path to approval. Imho, we will see much revenue prior to full approval.
This would get us past Fife, warrants, $10 & allow for uplist & serious fundraising (if needed). Revenue alone might cover all the costs.
This would translate to a negotiator's dream job.
We all know of approvals that resulted in losses because of market constraints.
CYDY starts cashing checks day 1. Because of the wizardry & guts of NP(not 13d), we have product to sell months ahead of any approval. And sell it we will.
In this case, it is more about the path to success than the path to approval. Imho, we will see much revenue prior to full approval.
This would get us past Fife, warrants, $10 & allow for uplist & serious fundraising (if needed). Revenue alone might cover all the costs.
This would translate to a negotiator's dream job.
We all know of approvals that resulted in losses because of market constraints.
CYDY starts cashing checks day 1. Because of the wizardry & guts of NP(not 13d), we have product to sell months ahead of any approval. And sell it we will.
(4)
(0)
